TABLE 1.
Liver and Coagulopathy in Patients with COVID‐19, Clinical Study
| Authors | Patients | Rate of | Patients With Liver Injury Had High Level of | Thrombus | ||||
|---|---|---|---|---|---|---|---|---|
| Liver Injury | ESR | Fibrinogen | D‐Dimer | FDP | Portal | Venous | ||
| McConnell et al.( 94 ) | 3,780 | 1,006 (27%) (ALT >3×) | NA | X | X | NA | NA | NA |
| Lu et al.( 127 ) | 1,361 | 125 (9%) (ALT >5× & AST >3×) | NA | NA | X | NA | NA | NA |
| Wang et al.( 128 ) | 657 | 303 (46%) (ALT >1×) | X | NA | NA | NA | NA | NA |
| Tsutsumi et al.( 129 ) | 60 | 31 (52%) (ALT >40 U/L) | NA | X | X | X | NA | NA |
| La Mura et al.( 12 ) | 1 | 1 (ALT 257 U/L) | NA | X | X | NA | X (CT) | |
| Del Hoyo et al.( 130 ) | 1 | 1 (ALT 1,065 U/L) | NA | NA | X | NA | X (CT) | |
| Franco‐Moreno et al.( 121 ) | 1 | 1 (ALT 111 U/L) | NA | X | X | NA | X (CT) | |
| Abeysekera et al.( 131 ) | 1 | 1 (ALT 55 U/L) | NA | NA | NA | NA | X (CT) | |
| Borazjani et al.( 132 ) | 1 | 1 (ALT 67 U/L) | NA | NA | NA | NA | X (CT) | |
| Randhawa et al.( 133 ) | 1 | None | NA | NA | NA | NA | X (CT) | |
| Sh Hassan et al.( 134 ) | 1 | 1 (ALT 1,325 U/L) | NA | NA | NA | NA | X (CT) | |
| Kolli and Oza( 135 ) | 1 | None | NA | NA | NA | NA | X (CT) | |
| Jeilani et al.( 136 ) | 1 | 1 (ALT 41 U/L) | NA | NA | X | NA | X (CT) | |
Abbreviations: AST, aspartate aminotransferase; CT, computed tomography; ESR, erythrocyte sedimentation rate; FDP, fibrin/fibrinogen degradation products; NA, not available; X, present.